Analyst firms · Barclays · DXCM
Barclays DXCM price target and rating history
DexCom Inc. (DXCM) · Health Care
Barclays rates DexCom Inc. (DXCM) Overweight with a $115 price target, as of its latest action on Oct 7, 2026. It has published 3 rating actions on DXCM since October 2022, including 0 upgrades and 1 downgrade. Across 5 firms with a DXCM price target in the last 12 months, the median target is $86. Barclays's $115 is 34% above that.
- Current rating
- Overweight
- Price target
- $115
- Median target, all firms
- $86
- Actions on DXCM
- 3
Barclays price target on DXCM
Every Barclays rating on DXCM
- Oct 7, 2026
- Jan 12, 2026
- Oct 18, 2022
How other firms rate DXCM
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $115 | Oct 7, 2026 |
| Deutsche Bank | Buy | $86 | Jun 23, 2026 |
| The Benchmark Company | Buy | $77 | May 12, 2026 |
| Evercore ISI | Outperform | $90 | Mar 24, 2026 |
| Morgan Stanley | Overweight | $75 | Dec 2, 2025 |
Questions about Barclays and DXCM
- What is Barclays's price target for DXCM?
- Barclays's latest stated price target for DexCom Inc. (DXCM) is $115, from its action on Oct 7, 2026.
- What is Barclays's rating on DXCM?
- Barclays rates DXCM Overweight, a bullish rating, as of Oct 7, 2026.
- When did Barclays last change its view on DXCM?
- On Oct 7, 2026, Barclays starts coverage at Overweight, price target $115.
- How does Barclays's DXCM target compare with other analysts?
- Across 5 firms with a DXCM price target in the last 12 months, the median target is $86. Barclays's $115 is 34% above that.
More DXCM rating histories
All Barclays ratingsDXCM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.